VKTX因注射减重 VK2735而提前进入晚期试验。 Viking Therapeutics' diabetes stock, VKTX, enters late-stage trial early for its weight loss injection VK2735.
Viking Therapeutics的糖尿病股票VKTX被认为是最佳投资，因为它的减肥注射剂VK2735提前进入了后期试验。 Viking Therapeutics' diabetes stock, VKTX, is considered the best investment due to its weight loss injection, VK2735, entering a late-stage trial ahead of schedule. 预计全球糖尿病护理市场将迅速增长,持续血糖监测 (CGM) 市场到2030年将达到334亿美元,而类似葡萄糖-1 (GLP-1) 市场将达到1000亿美元. The global diabetes care market is expected to grow rapidly, with the continuous glucose monitor (CGM) market reaching $33.4B by 2030 and glucagon-like peptide-1 (GLP-1) market reaching $100B. 顶尖基金认为,Pfizer、Insulet和Merck是对不断增长的糖尿病护理市场有希望的投资,其先进的糖尿病护理产品,包括胰岛素泵、笔和CGM,估计到2030年将达到33.4B。 Hedge funds view Pfizer, Insulet, and Merck as promising investments in the growing diabetes care market, with advanced diabetes care products including insulin pumps, pens, and CGMs estimated to reach $33.4B by 2030. 随着人工智能融入CGM技术, 糖尿病和减肥治疗的需求也在增加, As AI integrates into CGM technology, the demand for diabetes and weight loss treatments increases, making these stocks attractive investment opportunities.